Lynparza Combo Approved in EU as First-line Maintenance for Advanced Ovarian Cancer

Lynparza Combo Approved in EU as First-line Maintenance for Advanced Ovarian Cancer
The European Commission has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who responded to platinum-based chemotherapy. This indication also includes patients with advanced fallopian tube cancer or primary peritoneal cancer. Eligible HRD-positive tumors are those carrying mutations in the BRCA genes, involved in DNA repair, and/or exhibiting genomic instability (a high frequency of mutations within the genome). The decision comes less than two months after the Committee for Medicinal Products for Human Use, a branch of the European Medicines Agency, issued a positive recommendation, and six months after a similar approval in the U.S. The combination therapy also is being reviewed by regulatory agencies in Japan and other
Subscribe or to access all post and page content.